4 citations
,
November 2024 in “Cell Biology and Toxicology” Blocking certain receptors in the lungs might help treat a specific type of asthma.
January 2024 in “Wiadomości Lekarskie” COPD flare-ups worsen life quality and increase hospital visits and costs.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
8 citations
,
January 2024 in “Microorganisms” Dupilumab improves skin microbiome balance in atopic dermatitis patients.
January 2025 in “Dermatology Research and Practice” Higher activity in lichen planopilaris is linked to certain immune and tissue genes.
May 2017 in “Journal of The American Academy of Dermatology” PLAU and SerpinB2 affect cell death differently in various forms of leprosy and could be targets for new treatments.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” Montelukast is linked to increased risks of suicidal thoughts and depression.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
1 citations
,
March 2024 in “BioDrugs” Biologics for severe asthma have known side effects, but some new risks need more study.
39 citations
,
May 2014 in “Frontiers in Pharmacology” Special immune cells called Tregs can help prevent lung scarring by blocking a specific growth factor.
February 2023 in “Reactions Weekly”
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
12 citations
,
December 2022 in “Current Protein and Peptide Science” Thymosin β4 helps in cell activities, healing, and organ preservation, and treats hair loss and skin injuries.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” DHT may reduce inflammation caused by certain bacteria in skin cells.
April 2018 in “Journal of Investigative Dermatology” Acne patients' skin, both with and without lesions, shows a strong immune response and higher antimicrobial activity.
16 citations
,
April 2024 in “Proceedings of the National Academy of Sciences” HDAC4 and HDAC7 are crucial for Th17 cell development and could be targeted to treat inflammatory diseases.
June 2024 in “Journal of Allergy and Clinical Immunology” TSLP affects atopic dermatitis by increasing sebum and reducing fat through IL-4/IL-13 signaling.
28 citations
,
January 2016 in “Vitamins and hormones” Thymosin β4 helps improve skin healing and reduce scarring.
3 citations
,
November 1998 in “PubMed” July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
April 1992 in “Current opinion in therapeutic patents” New steroids were patented as effective for treating acne, hair loss, and other conditions related to hormones.
April 2016 in “Journal of Investigative Dermatology” A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.
71 citations
,
May 2019 in “Rheumatology” Tph cells are linked to the severity of systemic lupus erythematosus.
1 citations
,
May 2022 in “Frontiers in Pharmacology” Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.
58 citations
,
March 2019 in “Frontiers in Pharmacology” Wedelolactone may help treat lung fibrosis by reducing inflammation and lung damage.
November 2025 in “Journal of Investigative Dermatology” Certain immune cells in atopic dermatitis skin could be targeted for treatment.
10 citations
,
November 2017 in “Letters in drug design & discovery” Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
37 citations
,
November 2007 in “Journal of Biological Chemistry” Ku80 is a key receptor for Thymosin β4, affecting cell migration and wound healing.
March 2026 in “Folia Histochemica et Cytobiologica” LTBP1 is a key regulator in diseases and a potential target for new treatments.
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.